Has Novavax Just Solved Its Biggest Problem?

Many investors have seen Novavax (NVAX 3.97%) as a promising recovery story ever since the biotech launched a plan to cut costs to better match the revenue opportunities ahead of it. Once one of the biggest coronavirus vaccine hopefuls, Novavax's shares soared by more than 2,700% in 2020 -- then plummeted as the development and commercialization of the company's COVID vaccine candidate lagged behind its rivals.The late arrival of Novavax's vaccine on the market meant the company missed out on the early mult ...